Schedule 13G ownership disclosure

Apellis Pharmaceuticals Inc

Common Stock · CUSIP: 03753U106

Event date: 2024-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Morgan Stanley

    Shares: 9,592,751 · Class: 7.7%

  • Morgan Stanley Capital Services LLC

    Shares: 7,803,185 · Class: 6.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000895421-25-000177
Form type
SCHEDULE 13G
Filer
Apellis Pharmaceuticals, Inc.
CIK
CIK 1492422
Filed
Feb 03, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub